Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Int J Mol Sci. 2024 May 4;25(9):5023. doi: 10.3390/ijms25095023.
Melanoma is the most severe and fatal form of skin cancer, resulting from multiple gene mutations with high intra-tumor and inter-tumor molecular heterogeneity. Treatment options for patients whose disease has progressed beyond the ability for surgical resection rely on currently accepted standard therapies, notably immune checkpoint inhibitors and targeted therapies. Acquired resistance to these therapies and treatment-associated toxicity necessitate exploring novel strategies, especially those that can be personalized for specific patients and/or populations. Here, we review the current landscape and progress of standard therapies and explore what personalized oncology techniques may entail in the scope of melanoma. Our purpose is to provide an up-to-date summary of the tools at our disposal that work to circumvent the common barriers faced when battling melanoma.
黑色素瘤是最严重和致命的皮肤癌形式,是由多种基因突变引起的,具有高肿瘤内和肿瘤间的分子异质性。对于那些疾病已经发展到无法通过手术切除的患者,治疗选择依赖于目前公认的标准治疗方法,特别是免疫检查点抑制剂和靶向治疗。对这些治疗方法的获得性耐药性和治疗相关毒性需要探索新的策略,特别是那些可以针对特定患者和/或人群进行个性化的策略。在这里,我们回顾了标准治疗的现状和进展,并探讨了个性化肿瘤学技术在黑色素瘤领域可能涉及的内容。我们的目的是提供一个最新的综述,介绍我们目前用来克服治疗黑色素瘤时常见障碍的工具。
Int J Mol Sci. 2024-5-4
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2014-12-19
Cochrane Database Syst Rev. 2023-1-17
Cochrane Database Syst Rev. 2015-12-1
Cochrane Database Syst Rev. 2015-5-16
J Cancer Res Clin Oncol. 2021-5
Future Oncol. 2025-7
Skin Health Dis. 2025-4-22
Biomedicines. 2024-8-14
Diagnostics (Basel). 2024-6-21
Front Immunol. 2023
Pharmacol Rep. 2023-10
Cell Death Dis. 2023-7-26